Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic

Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.
by mikkel aabenhus hemmingsen, translated by catherine brett

According to the CEO of an influential diabetes center in Copenhagen, Novo Nordisk has gained a worthy opponent within the diabetes indication in the form of Eli Lilly’s Mounjaro (tirzepatide), which was recently approved in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading